SCHEMBL4260779

SCHEMBL4260779

O=C(Nc1ccc(-c2nc(-c3ccccc3)co2)c(Cl)c1)c1ccc(Cl)cc1Cl

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 5/20 0.64
KMT2A Q03164 6/20 0.54
MEN1 O00255 5/20 0.54
MAPT P10636 3/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
KDM4E B2RXH2 2/20 0.54
GAA P10253 1/20 0.54
CYP2C19 P33261 1/20 0.52
HPSE Q9Y251 1/20 0.51
GPR27 Q9NS67 2/20 0.48
AVPR2 P30518 1/20 0.48
JAK2 O60674 1/20 0.48
JAK1 P23458 1/20 0.48
TYK2 P29597 1/20 0.48
CNR1 P21554 1/20 0.47
ATM Q13315 1/20 0.46
APOBEC3A P31941 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4255803 0.91 SMO (0.78) SMOKMT2AMEN1MAPTCYP2C19
SCHEMBL4254933 0.89 SMO (0.79) SMOKMT2AMEN1MAPTNPC1
SCHEMBL4257702 0.86 SMO (0.60) SMOKMT2AMEN1MAPTNPC1
SCHEMBL4257905 0.82 SMO (0.67) SMOKMT2AMEN1MAPTNPC1
SCHEMBL4262096 0.81 SMO (0.66) SMOKMT2AMEN1MAPTNPC1
SCHEMBL4255752 0.80 SMO (0.64) SMOKMT2AMEN1MAPTNPC1
SCHEMBL4255817 0.78 SMO (1.00) SMOKMT2AMEN1MAPTCYP2C19
SCHEMBL4263844 0.78 SMO (0.59) SMOKMT2AMAPTNPC1RAB9A
SCHEMBL12515159 0.78 MEN1 (0.62) SMOKMT2AMEN1MAPTNPC1
SCHEMBL4253028 0.76 SMO (0.81) SMOKMT2AMEN1MAPTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404722-B2 Oxazole compounds compositions and methods of use AMGEN INC. (US) 2013-03-26 US claimed
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2011-03-10 US claimed
WO-2009151495-A2 OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2009-12-17 WO claimed
US-8404722-B2 Oxazole compounds compositions and methods of use AMGEN INC. (US) 2013-03-26 US disclosed
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2011-03-10 US disclosed
WO-2009151495-A2 OXAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060011-A1 OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE OXA1L, CYP11B2, CYP3A7 SMO 1063/4885KMT2A 3053/4885MEN1 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.